BullMarket.com Offers Investment Opinion on CROs.

PRINCETON, N.J. -- Bullmarket.com (http://www.bullmarket.com), an online investment newsletter focused on long-term growth and income-generating stocks, announced today that it has provided subscribers with a report on clinical research organizations (CROs), including Covance (NYSE: CVD), Pharmaceutical Product Development (Nasdaq: PPDI), Parexel (NYSE: PRXL), Charles River Laboratories (NYSE: CRL), and WuXi PharmaTech (NYSE: WX), among others.

All paid and trial subscribers to BullMarket.com can now receive immediate access to the newsletter's exclusive daily reports. As a subscriber, you'll also gain access to our latest investment moves. Start your 14-day free trial today:

https://www.bullmarket.com/subscribe/index.php?refer=BMR328B

In its report, BullMarket.com wrote: "The CRO industry began in the U.S., but it has grown to be a global business. Along with industry growth, another trend is for the actual trials to go global, mirroring developments in other industries that have gone overseas to cut expenses. India has become a leading player in the drug testing space, while China and Eastern European countries are also in the mix. CROs, in turn, have expanded their footprint around the world by opening offices in many of these regions."

BullMarket.com looked at the following topics, among others:

-- With Covance up over 35% since BullMarket.com first profiled it, is the stock still a buy?

-- How is Pharmaceutical Product Development's business model different from other CROs, and is this good for investors?

-- Trading at a discount to Covance with a similar recent stock performance, does Charles River look like the better bargain?

-- What advantage may Parexel have over some of its peers?

-- Does WuXi PharmaTech look well positioned for the outsourcing of pharmaceutical research overseas?

About BullMarket.com:

Launched in 1997, BullMarket.com has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The BullMarket.com Recommended List includes about 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. BullMarket.com is one of the oldest continuously published investment newsletters online, and its Recommended List has consistently outperformed the major market indices.

NOTE: This release was published by Indie Research Advisors, LLC (CRD #131926), a registered investment advisor with the NASD and State of NJ. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

SOURCE: Indie Research Advisors, LLC